Intuitive Surgical, Inc. $ISRG Shares Purchased by Alyeska Investment Group L.P.

Key Points

• Alyeska Investment Group L.P. increased its stake in Intuitive Surgical, Inc. by 55.2% in the 1st quarter, owning 302,684 shares valued at approximately $149.9 million.
• Equities analysts have generally given Intuitive Surgical a positive outlook, with an average target price of $595.95 and 13 analysts rating it as a Buy.
• Insider trading has seen significant activity, with executives selling over 44,000 shares in the last 90 days, highlighting a 92.73% decrease in position for one EVP.

Alyeska Investment Group L.P. boosted its holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 55.2% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund owned 302,684 shares of the medical equipment provider's stock after buying an additional 107,668 shares during the quarter. Alyeska Investment Group L.P. owned 0.08% of Intuitive Surgical worth $149,910,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. Brighton Jones LLC boosted its stake in Intuitive Surgical by 24.9% in the 4th quarter. Brighton Jones LLC now owns 3,672 shares of the medical equipment provider's stock worth $1,916,000 after purchasing an additional 731 shares during the period. Bank Pictet & Cie Europe AG boosted its stake in Intuitive Surgical by 0.5% in the 4th quarter. Bank Pictet & Cie Europe AG now owns 190,969 shares of the medical equipment provider's stock worth $99,678,000 after purchasing an additional 883 shares during the period. Algert Global LLC boosted its stake in Intuitive Surgical by 115.7% in the 4th quarter. Algert Global LLC now owns 8,727 shares of the medical equipment provider's stock worth $4,555,000 after purchasing an additional 4,681 shares during the period. Baird Financial Group Inc. boosted its stake in Intuitive Surgical by 23.4% in the 4th quarter. Baird Financial Group Inc. now owns 45,118 shares of the medical equipment provider's stock worth $23,550,000 after purchasing an additional 8,551 shares during the period. Finally, Cary Street Partners Financial LLC acquired a new position in Intuitive Surgical in the 4th quarter worth approximately $220,000. Institutional investors and hedge funds own 83.64% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the stock. Wall Street Zen raised shares of Intuitive Surgical from a "hold" rating to a "buy" rating in a research note on Saturday, July 26th. Royal Bank Of Canada reaffirmed an "outperform" rating and issued a $615.00 price objective on shares of Intuitive Surgical in a research note on Tuesday, August 19th. Citigroup reaffirmed a "buy" rating and issued a $650.00 price objective (up previously from $590.00) on shares of Intuitive Surgical in a research note on Thursday, May 22nd. UBS Group raised their price objective on shares of Intuitive Surgical from $547.00 to $585.00 and gave the stock a "neutral" rating in a research note on Wednesday, July 23rd. Finally, Erste Group Bank reissued a "hold" rating on shares of Intuitive Surgical in a research note on Wednesday, July 23rd. Thirteen equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $595.95.

Intuitive Surgical Stock Down 0.9%

Shares of NASDAQ:ISRG opened at $469.07 on Wednesday. The firm has a fifty day moving average of $498.54 and a two-hundred day moving average of $515.81. The firm has a market capitalization of $168.15 billion, a P/E ratio of 65.42, a price-to-earnings-growth ratio of 4.96 and a beta of 1.61. Intuitive Surgical, Inc. has a 12-month low of $425.00 and a 12-month high of $616.00.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last issued its earnings results on Tuesday, July 22nd. The medical equipment provider reported $2.19 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.93 by $0.26. The company had revenue of $2.44 billion during the quarter, compared to analyst estimates of $2.35 billion. Intuitive Surgical had a net margin of 28.51% and a return on equity of 14.56%. The company's revenue for the quarter was up 21.4% on a year-over-year basis. During the same quarter last year, the business posted $1.78 EPS. Equities research analysts expect that Intuitive Surgical, Inc. will post 6.43 earnings per share for the current fiscal year.

Insider Activity

In other news, EVP Myriam Curet sold 4,500 shares of the firm's stock in a transaction on Friday, July 25th. The shares were sold at an average price of $492.48, for a total transaction of $2,216,160.00. Following the transaction, the executive vice president owned 353 shares in the company, valued at approximately $173,845.44. This trade represents a 92.73% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Mark Brosius sold 216 shares of the firm's stock in a transaction on Friday, June 6th. The shares were sold at an average price of $563.11, for a total transaction of $121,631.76. Following the transaction, the senior vice president owned 907 shares in the company, valued at $510,740.77. This represents a 19.23% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 44,769 shares of company stock worth $21,532,536. 0.70% of the stock is owned by corporate insiders.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.